On Thursday, Oppenheimer maintained its Outperform rating on Kymera Therapeutics (NASDAQ:KYMR) but lowered the price target to $52 from $53. The adjustment follows Kymera's first-quarter results and an in-depth presentation of the company's plans and timelines for its portfolio. The focus in the near term is on the STAT6 program, with a preclinical update expected at the American Thoracic Society (ATS) meeting soon, and further data from oncology programs anticipated at the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) in June.
Kymera reported first-quarter operating expenses of $68 million, which was slightly above the estimates of $64.5 million by Oppenheimer and $66.1 million consensus. However, this was partly offset by collaboration revenues amounting to $10.3 million. The company also announced a first-quarter ending cash position of $745 million, which is projected to sustain operations comfortably into the first half of 2027.
The revised price target reflects an update to Oppenheimer's financial model, which includes adjustments to the share count. This recalibration resulted in a $1 decrease in the price target to the current $52. Despite this change, the firm reiterates its positive outlook on the stock.
InvestingPro Insights
As Kymera Therapeutics (NASDAQ:KYMR) navigates through its clinical updates and financials, real-time data from InvestingPro provides additional context for investors. Kymera's market capitalization stands at $2.23 billion, reflecting its position in the market. Despite a negative P/E ratio of -14.38, which indicates that the company is not currently profitable, Kymera has shown impressive revenue growth of 70.16% over the last twelve months as of Q1 2024. This growth is an important metric for investors, as it may signal the company's potential despite current losses.
InvestingPro Tips highlight that Kymera holds more cash than debt on its balance sheet, which is a strong indicator of financial health and may provide some reassurance to investors about the company's ability to fund its operations. Additionally, analysts have revised their earnings upwards for the upcoming period, suggesting optimism about the company's future performance. On the flip side, it's important to note that analysts anticipate a sales decline in the current year and do not expect the company to be profitable this year.
For those seeking further insights, there are additional InvestingPro Tips available, which can provide a deeper dive into Kymera's financial health and future prospects. By using the coupon code PRONEWS24, investors can receive an additional 10% off a yearly or biyearly Pro and Pro+ subscription. This offer is especially valuable for those looking to stay ahead with comprehensive analysis and real-time data.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.